Global Osteoporosis Market & Drugs Analysis 2010 - 2015
Buy NowOsteoporosis Market Overview
Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture. Global osteoporosis market is expected to reach 16 Billion by 2015. This significant growth is primarily attributed to strong treatment options currently available in the market as well as strong pipeline products. The increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future.
Fosamax was the undisputed leading product in the history of global osteoporosis drug market till 2007. It has a market share of nearly 37% in 2007 but, declined to 5% by 2015 due to patent expiry and competition from cheaper generics. Boniva and Evista were leading the osteoporosis market till 2010 but the dynamics of osteoporosis market is expected to change by 2011 as Prolia is going to be introduced in the market. It is predicted that Prolia will lead the market with nearly 45% share by 2015.
The osteoporosis market offers multiple opportunities for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. While the market awaits new growth, driven by the launch of several promising pipeline drugs, including Amgen’s Prolia (denosumab), companies are looking for innovative ways to maximize revenues from their products nearing the end of their lifecycles.
Report Details
“Global Osteoporosis Market & Drugs Analysis 2010 – 2015” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:
• Global Osteoporosis Market (2009 to 2015)
• Four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin) market and market
share data of (2006 to 2014)
• Top Nine Osteoporosis Drug Brand (Fosamax, Actonel, Reclast, Boniva, Evista, Forteo,
Viviant/Conbriza, Miacalcin, Prolia) sales and market share data of 2007 to 2015
• Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market share data of
(2009 to 2015)
• Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market data of (2005
to 2015)
• Pipeline Developmental Agents (Odanacatib, Aprela) Future Trends
• Key Companies (Eli Lilly, Roche, Amgen, Merck & Novartis) Analysis – Revenue in Osteoporosis
Market (2007 to 2010), Strength & Weakness in Osteoporosis Market
Research Highlights
• Global Osteoporosis drug market is expected to reach the figure of US$ 16 Billion by 2015
• United States Osteoporosis drug market was nearly US$ 5 Billion in 2010
• United States & China together is expected to control 61% market share in osteoporosis drug market
by 2015
• Although SERM is increasing its market share year on year but Bisphosphonates will continue to
dominate the osteoporosis drug class segment with 56% in 2014
• Prolia will lead the Osteoporosis drug market with 45% share by 2015
Data Sources
Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, News websites, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
1. Executive Summary
2. Global Osteoporosis Market
3. Global Osteoporosis Market Share (2007 – 2015)
3.1 By Drug Class - Osteoporosis Market Share & Forecast
3.2 By Drug Market Share - Osteoporosis Market Share & Forecast
3.3 By Country (USA, European Union, Japan, China, India, Korea) - Osteoporosis Drug Market Share & Forecast
4. By Country – Osteoporosis Market & Forecast (2008 – 2015)
4.1 United States Osteoporosis Market & Forecast
4.2 European Union Osteoporosis Market & Forecast
4.3 Japan Osteoporosis Market & Forecast
4.4 China Osteoporosis Market & Forecast
4.5 Korea Osteoporosis Market & Forecast
4.6 India Osteoporosis Market & Forecast
5. Osteoporosis Drugs Classes Market & Forecast (2004 – 2014)
5.1 Global Bisphosphonate Market & Forecast
5.2 Global Selective Estrogen Receptor Modulators (SERM) Market & Forecast
5.3 Global Parathyroid Hormone (PTH) Market & Forecast
5.4 Global Calcitonin Market & Forecast
6. Osteoporosis Drugs Market Analysis & Forecast (2004 – 2015)
6.1 Bisphosphonate Drugs Market & Forecast
6.1.1 Fosamax (Alendronate)
6.1.2 Bonviva/Boniva (Ibandronic Acid)
6.1.3 Reclast/Aclasta
6.1.4 Actonel (Risedronate)
6.2 SERMs Drugs Market & Forecast
6.2.1 Evista (Raloxifene)
6.2.2 Viviant/ Conbriza (Bazedoxifene)
6.3 Parathyroid Hormone Drugs Market & Forecast
6.3.1 Forteo
6.4 Calcitonin Drugs Market & Forecast
6.4.1 Miacalcin
6.5 Prolia (Denosumab)
7. Pipeline Drugs in Osteoporosis Market Analysis
7.1 Odanacatib (MK 0822)
7.2 Aprela (Bazedoxifene)
8. Licensing Deals in Osteoporosis Drug Market (2008 – 2009)
9. Key Companies Analysis
9.1 Eli Lilly
9.1.1 Eli Lilly Revenue in Osteoporosis Segment
9.1.2 Strength
9.1.3 Weaknesses
9.2 Roche
9.2.1 Roche Revenue in Osteoporosis Segment
9.2.2 Strength
9.2.3 Weaknesses
9.3 Amgen
9.3.1 Strength
9.3.2 Weaknesses
9.4 Merck
9.4.1 Merck Revenue in Osteoporosis Segment
9.4.2 Strength
9.4.3 Weaknesses
9.5 Novartis
9.5.1 Novartis Revenue in Osteoporosis Segment
9.5.2 Strength
9.5.3 Weaknesses
List of Figures:
Figure 2 1: Global – Osteoporosis Market (Million US$), 2009 – 2010
Figure 2 2: Global – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
Figure 3 1: Global – Osteoporosis Drug Class Market Share (Percent), 2006 – 2010
Figure 3 2: Global – Forecast for Osteoporosis Drug Class Market Share (Percent), 2011 – 2014
Figure 3 3: Global – Osteoporosis Drug Market Share (Percent), 2007 – 2010
Figure 3 4: Global – Forecast for Osteoporosis Drug Market Share (Percent), 2011 – 2015
Figure 3 5: Global – Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2009 – 2010
Figure 3 6: Global – Forecast for Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2011 – 2015
Figure 4 1: United States – Osteoporosis Market (Million US$), 2008 – 2010
Figure 4 2: United States – Forecast for Osteoporosis Market (Million US$), 2011 – 2021
Figure 4 3: European Union – Osteoporosis Market (Million US$), 2009 – 2010
Figure 4 4: European Union – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
Figure 4 5: Japan – Osteoporosis Market (Billion Yen), 2001 – 2010
Figure 4 6: Japan – Forecast for Osteoporosis Market (Billion Yen), 2011 – 2015
Figure 4 7: China – Osteoporosis Market (Million US$), 2004 – 2010
Figure 4 8: China – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
Figure 4 9: Korea – Osteoporosis Market (Million US$), 2001 – 2010
Figure 4 10: Korea – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
Figure 4 11: India – Osteoporosis Market (Million INR), 2007 – 2010
Figure 4 12: India – Forecast for Osteoporosis Market (Million INR), 2011 – 2015
Figure 5 1: Global – Bisphosphonate Market (Million US$), 2004 – 2010
Figure 5 2: Global – Forecast for Bisphosphonate Market (Million US$), 2011 – 2014
Figure 5 3: Global – SERM Market (Million US$), 2004 – 2010
Figure 5 4: Global – Forecast for SERM Market (Million US$), 2011 – 2014
Figure 5 5: Global – PTH Market (Million US$), 2004 – 2010
Figure 5 6: Global – Forecast for PTH Market (Million US$), 2011 – 2014
Figure 5 7: Global – Calcitonin Market (Billion US$), 2004 – 2010
Figure 5 8: Global – Forecast for Calcitonin Market (Billion US$), 2004 – 2010
Figure 6 1: Global – Fosamax Drug Sales (Million US$), 2003 – 2010
Figure 6 2: Global – Forecast for Fosamax Drug Sales (Million US$), 2011 – 2015
Figure 6 3: Global – Boniva Drug Sales (Million US$), 2005 – 2010
Figure 6 4: Global – Forecast for Boniva Drug Sales (Million US$), 2011 – 2015
Figure 6 5: Global – Reclast/Aclasta Drug Sales (Million US$), 2007 – 2010
Figure 6 6: Global – Forecast for Reclast/Aclasta Drug Sales (Million US$), 2011 – 2015
Figure 6 7: Global – Actonel Drug Sales (Million US$), 2004 – 2010
Figure 6 8: Global – Forecast for Actonel Drug Sales (Million US$), 2011 – 2013
Figure 6 10: Global – Evista Drug Sales (Million US$), 2001 – 2010
Figure 6 11: Global – Forecast for Evista Drug Sales (Million US$), 2011 – 2015
Figure 6 12: Global – Viviant/Conbriza Drug Sales (Million US$), 2010 – 2015
Figure 6 13: Global – Forteo Drug Sales (Million US$), 2003 – 2010
Figure 6 14: Global – Forecast for Forteo Drug Sales (Million US$), 2011 – 2015
Figure 6 15: Global – Miacalcin Drug Sales (Million US$), 2004 – 2010
Figure 6 16: Global – Forecast for Miacalcin Drug Sales (Million US$), 2011 – 2015
Figure 6 17: Global – Forecast for Prolia Drug (Million US$), 2010 – 2016
Figure 7 1: Global – Forecast for Odanacatib Drug (Million US$), 2012 – 2015
Figure 7 2: Global – Forecast for Aprela Drug Sales (Million US$), 2011 – 2015
Figure 9 1: Eli Lilly – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
Figure 9 2: Roche – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
Figure 9 3: Merck – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
Figure 9 4: Novartis – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
List of Tables:
Table 6 1: Actonel (Eisai, P&G and Sanofi-Aventis) – Sales (Million US$), 2004 – 2013
Table 6 2: Benet (Risedronate) – Sales (Million US$), 2004 – 2013
Table 9 1: Osteoporosis – Drugs Cost Comparison (US$) in 1 Year
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com